MA62992B1 - Formulations de capsules - Google Patents
Formulations de capsulesInfo
- Publication number
- MA62992B1 MA62992B1 MA62992A MA62992A MA62992B1 MA 62992 B1 MA62992 B1 MA 62992B1 MA 62992 A MA62992 A MA 62992A MA 62992 A MA62992 A MA 62992A MA 62992 B1 MA62992 B1 MA 62992B1
- Authority
- MA
- Morocco
- Prior art keywords
- compound
- solid solution
- capsule formulations
- capsules
- suffering
- Prior art date
Links
- 239000007963 capsule composition Substances 0.000 title abstract 2
- 239000002775 capsule Substances 0.000 abstract 3
- AICOOMRHRUFYCM-ZRRPKQBOSA-N oxazine, 1 Chemical compound C([C@@H]1[C@H](C(C[C@]2(C)[C@@H]([C@H](C)N(C)C)[C@H](O)C[C@]21C)=O)CC1=CC2)C[C@H]1[C@@]1(C)[C@H]2N=C(C(C)C)OC1 AICOOMRHRUFYCM-ZRRPKQBOSA-N 0.000 abstract 3
- 239000006104 solid solution Substances 0.000 abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 102000005590 Anaphylatoxin C5a Receptor Human genes 0.000 abstract 1
- 108010059426 Anaphylatoxin C5a Receptor Proteins 0.000 abstract 1
- 230000004913 activation Effects 0.000 abstract 1
- 229940125904 compound 1 Drugs 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000001575 pathological effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4816—Wall or shell material
- A61K9/4825—Proteins, e.g. gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4833—Encapsulating processes; Filling of capsules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Heart & Thoracic Surgery (AREA)
- Inorganic Chemistry (AREA)
- Cardiology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
La présente invention concerne des formulations de capsules en solution solide du composé 1.L'invention concerne également des procédés de traitement d'individus souffrant ou susceptibles de souffrir d'une maladie ou d'un trouble impliquant une activation pathologique des récepteurs C5a, par administration d'une quantité efficace d'une ou de plusieurs capsules de solution solide comprenant le composé 1. L'invention concerne également des capsules de dosage à unité unique comprenant certaines quantités du composé 1, et des kits comprenant une capsule de solution solide comprenant le composé 1.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862773848P | 2018-11-30 | 2018-11-30 | |
| EP23160271.5A EP4233850B1 (fr) | 2018-11-30 | 2019-11-27 | Formulations de capsules |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA62992B1 true MA62992B1 (fr) | 2025-01-31 |
Family
ID=70849818
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA54318A MA54318B1 (fr) | 2018-11-30 | 2019-11-27 | Formulations de capsules |
| MA62992A MA62992B1 (fr) | 2018-11-30 | 2019-11-27 | Formulations de capsules |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA54318A MA54318B1 (fr) | 2018-11-30 | 2019-11-27 | Formulations de capsules |
Country Status (30)
| Country | Link |
|---|---|
| US (4) | US20200170957A1 (fr) |
| EP (3) | EP4487915A3 (fr) |
| JP (1) | JP7342124B2 (fr) |
| KR (1) | KR102586747B1 (fr) |
| CN (1) | CN113164403A (fr) |
| AR (1) | AR117219A1 (fr) |
| AU (1) | AU2019389031B2 (fr) |
| BR (1) | BR112021010285A2 (fr) |
| CA (1) | CA3120999C (fr) |
| CL (1) | CL2021001389A1 (fr) |
| CY (1) | CY1126079T1 (fr) |
| DK (2) | DK4233850T3 (fr) |
| ES (2) | ES2998858T3 (fr) |
| FI (2) | FI3886820T3 (fr) |
| HR (2) | HRP20241735T1 (fr) |
| HU (2) | HUE069633T2 (fr) |
| IL (1) | IL283450B2 (fr) |
| LT (2) | LT4233850T (fr) |
| MA (2) | MA54318B1 (fr) |
| MD (2) | MD4233850T2 (fr) |
| MX (1) | MX2021006242A (fr) |
| NZ (1) | NZ776554A (fr) |
| PL (2) | PL3886820T3 (fr) |
| PT (2) | PT3886820T (fr) |
| RS (2) | RS64250B1 (fr) |
| SG (1) | SG11202105572UA (fr) |
| SI (2) | SI4233850T1 (fr) |
| SM (2) | SMT202400521T1 (fr) |
| TW (1) | TWI827745B (fr) |
| WO (1) | WO2020112961A1 (fr) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK4233850T3 (da) | 2018-11-30 | 2025-01-02 | Chemocentryx Inc | Kapselformuleringer |
| BR112022007489A2 (pt) | 2019-11-08 | 2022-07-12 | Chemocentryx Inc | Forma amorfa de um receptor c5a de componente do complemento |
| CN116529241A (zh) * | 2020-10-28 | 2023-08-01 | 坎莫森特里克斯公司 | 治疗化脓性汗腺炎的方法 |
| CA3192880A1 (fr) * | 2020-10-28 | 2022-05-05 | Chemocentryx, Inc. | Methodes de traitement de l'hidradenite suppuree |
| KR20230124981A (ko) * | 2020-12-21 | 2023-08-28 | 케모센트릭스, 인크. | C5a 억제제를 사용한 c3 사구체병증의 치료 |
| CN119031903A (zh) * | 2022-05-19 | 2024-11-26 | 陶氏环球技术有限责任公司 | 基于peg的聚合物间复合物用于改善bcs ii类药物的增溶的用途 |
| WO2025203055A1 (fr) * | 2024-03-26 | 2025-10-02 | Council Of Scientific And Industrial Research | Formulation de dihydrofolate encapsulée pour supplémentation alimentaire en tant que supplément nutraceutique efficace et son procédé de préparation |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR038681A1 (es) | 2002-02-14 | 2005-01-26 | Solvay Pharm Bv | Formulacion oral de solucion solida de una sustancia activa pobremente soluble en agua |
| CA2587733A1 (fr) * | 2004-11-24 | 2006-06-01 | Merck & Co., Inc. | Formulations pharmaceutiques liquides et semi-solides pour administration par voie orale d'un amide substitue |
| DE102005053066A1 (de) | 2005-11-04 | 2007-05-10 | Basf Ag | Verwendung von Copolymeren als Solubilisatoren für in Wasser schwerlöslichen Verbindungen |
| EP4015504A1 (fr) | 2008-12-22 | 2022-06-22 | ChemoCentryx, Inc. | Antagonistes du c5ar |
| US20110312973A1 (en) | 2010-03-10 | 2011-12-22 | Bernd Liepold | Solid compositions |
| DK2585064T3 (en) | 2010-06-24 | 2017-07-24 | Chemocentryx Inc | C5aR antagonists |
| US9034858B2 (en) * | 2010-11-30 | 2015-05-19 | Lipocine Inc. | High-strength testosterone undecanoate compositions |
| US9074470B2 (en) | 2010-12-27 | 2015-07-07 | Seven Generations Energy Ltd. | Methods for drilling and stimulating subterranean formations for recovering hydrocarbon and natural gas resources |
| EA037895B1 (ru) | 2014-02-05 | 2021-06-02 | Лек Фармасьютикалз Д.Д. | Твердые фармацевтические композиции антагонистов рецепторов андрогенов |
| CA3220371A1 (fr) | 2014-09-29 | 2016-04-07 | Chemocentryx, Inc. | Procedes et intermediaires utilises dans la preparation d'antagonistes de c5ar |
| WO2017123716A1 (fr) | 2016-01-14 | 2017-07-20 | Chemocentryx, Inc. | Procédé de traitement d'une glomérulopathie à c3 |
| NZ747259A (en) | 2016-04-04 | 2022-11-25 | Chemocentryx Inc | Soluble c5ar antagonists |
| US10376595B2 (en) | 2017-04-03 | 2019-08-13 | Inflarx Gmbh | Treatment of inflammatory diseases with inhibitors of C5a activity |
| CN111108118A (zh) | 2017-04-03 | 2020-05-05 | 因弗拉克斯有限责任公司 | 用C5a活性抑制剂治疗炎性疾病 |
| US20190144389A1 (en) | 2017-10-30 | 2019-05-16 | Chemocentryx, Inc. | Deuterated compounds as immunomodulators |
| EP4671767A2 (fr) | 2017-10-31 | 2025-12-31 | ChemoCentryx, Inc. | Réduction d'inhibiteur de c5ar de scd163 urinaire |
| JP2021527062A (ja) | 2018-06-07 | 2021-10-11 | ケモセントリックス，インコーポレイティド | ＡＮＣＡ関連血管炎に対するｃ５ａアンタゴニストの投薬及び効果 |
| DK4233850T3 (da) | 2018-11-30 | 2025-01-02 | Chemocentryx Inc | Kapselformuleringer |
-
2019
- 2019-11-27 DK DK23160271.5T patent/DK4233850T3/da active
- 2019-11-27 LT LTEP23160271.5T patent/LT4233850T/lt unknown
- 2019-11-27 DK DK19889873.6T patent/DK3886820T3/da active
- 2019-11-27 SI SI201930868T patent/SI4233850T1/sl unknown
- 2019-11-27 MA MA54318A patent/MA54318B1/fr unknown
- 2019-11-27 PT PT198898736T patent/PT3886820T/pt unknown
- 2019-11-27 EP EP24196793.4A patent/EP4487915A3/fr active Pending
- 2019-11-27 ES ES23160271T patent/ES2998858T3/es active Active
- 2019-11-27 HR HRP20241735TT patent/HRP20241735T1/hr unknown
- 2019-11-27 SM SM20240521T patent/SMT202400521T1/it unknown
- 2019-11-27 IL IL283450A patent/IL283450B2/en unknown
- 2019-11-27 PT PT231602715T patent/PT4233850T/pt unknown
- 2019-11-27 PL PL19889873.6T patent/PL3886820T3/pl unknown
- 2019-11-27 RS RS20230433A patent/RS64250B1/sr unknown
- 2019-11-27 MX MX2021006242A patent/MX2021006242A/es unknown
- 2019-11-27 SI SI201930524T patent/SI3886820T1/sl unknown
- 2019-11-27 RS RS20241401A patent/RS66362B1/sr unknown
- 2019-11-27 KR KR1020217019883A patent/KR102586747B1/ko active Active
- 2019-11-27 FI FIEP19889873.6T patent/FI3886820T3/fi active
- 2019-11-27 LT LTEPPCT/US2019/063547T patent/LT3886820T/lt unknown
- 2019-11-27 SM SM20230153T patent/SMT202300153T1/it unknown
- 2019-11-27 JP JP2021531035A patent/JP7342124B2/ja active Active
- 2019-11-27 HU HUE23160271A patent/HUE069633T2/hu unknown
- 2019-11-27 EP EP19889873.6A patent/EP3886820B8/fr active Active
- 2019-11-27 CA CA3120999A patent/CA3120999C/fr active Active
- 2019-11-27 FI FIEP23160271.5T patent/FI4233850T3/fi active
- 2019-11-27 ES ES19889873T patent/ES2943492T3/es active Active
- 2019-11-27 HU HUE19889873A patent/HUE062551T2/hu unknown
- 2019-11-27 US US16/697,523 patent/US20200170957A1/en not_active Abandoned
- 2019-11-27 MD MDE20231131T patent/MD4233850T2/ro unknown
- 2019-11-27 AU AU2019389031A patent/AU2019389031B2/en active Active
- 2019-11-27 WO PCT/US2019/063547 patent/WO2020112961A1/fr not_active Ceased
- 2019-11-27 PL PL23160271.5T patent/PL4233850T3/pl unknown
- 2019-11-27 NZ NZ776554A patent/NZ776554A/en unknown
- 2019-11-27 MA MA62992A patent/MA62992B1/fr unknown
- 2019-11-27 EP EP23160271.5A patent/EP4233850B1/fr active Active
- 2019-11-27 CN CN201980079276.4A patent/CN113164403A/zh active Pending
- 2019-11-27 SG SG11202105572UA patent/SG11202105572UA/en unknown
- 2019-11-27 MD MDE20210972T patent/MD3886820T2/ro unknown
- 2019-11-27 BR BR112021010285-0A patent/BR112021010285A2/pt not_active Application Discontinuation
- 2019-11-27 HR HRP20230551TT patent/HRP20230551T1/hr unknown
- 2019-11-29 TW TW108143799A patent/TWI827745B/zh active
- 2019-11-29 AR ARP190103505A patent/AR117219A1/es unknown
-
2021
- 2021-05-27 CL CL2021001389A patent/CL2021001389A1/es unknown
- 2021-12-08 US US17/545,878 patent/US11951214B2/en active Active
-
2023
- 2023-07-03 CY CY20231100309T patent/CY1126079T1/el unknown
-
2024
- 2024-02-09 US US18/437,368 patent/US20240299306A1/en not_active Abandoned
-
2025
- 2025-08-28 US US19/313,405 patent/US20250375385A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA62992B1 (fr) | Formulations de capsules | |
| MA57412B1 (fr) | Benzopyrrole substitués et inhibiteurs du complément structurellement apparentés | |
| Heneka et al. | Neuroinflammation in Alzheimer's disease | |
| MA43817B1 (fr) | Méthodes de traitement de la dépression à l'aide d'antagonistes de récepteurs de l'orexine-2 | |
| WO2018215795A3 (fr) | Composés sénolytiques | |
| MA37829A1 (fr) | Combinaisons pharmaceutiques comprenant un inhibiteur de b-raf, un inhibiteur d'egfr et facultativement un inhibiteur de pi3k alpha | |
| MA51204B1 (fr) | Formes pharmaceutiques comprenant un inhibiteur de la kallicréine plasmatique | |
| MA44037B1 (fr) | Modulateurs du récepteur adrénergique bêta 3 utile dans le traitement ou la prévention de troubles associés à ceux-ci | |
| MA52288B1 (fr) | Modulateurs d'enzymes de modification de méthyle, compositions et utilisations de ceux-ci | |
| MA52219B1 (fr) | Traitement de l'hidradénite suppurée à l'aide d'inhibiteurs de jak | |
| EA201490279A1 (ru) | Ингибиторы кинуренин-3-монооксигеназы, фармацевтические композиции и способы их применения | |
| EA201490277A1 (ru) | Ингибиторы кинуренин-3-монооксигеназы, фармацевтические композиции и способы их применения | |
| EA201490163A1 (ru) | Ингибиторы кинуренин-3-монооксигеназы, фармацевтические композиции и способы их применения | |
| MA46665B1 (fr) | Composés de tyrosine tyrosine de peptide cyclique couplés à un anticorps en tant que modulateurs des récepteurs du neuropeptide y | |
| MA40768B1 (fr) | Dérivés d'indole mono ou di-substitué en tant qu'inhibiteurs de réplication du virus de la dengue | |
| EA202191955A1 (ru) | Таблетированные составы с модифицированным высвобождением, содержащие ингибиторы фосфодиэстеразы | |
| MA42301B1 (fr) | Sel cristallin de fumarate de (s)-[3,4-difluoro-2-(2-fluoro-4-iodophénylamino)phényl][3-hydroxy-3-(pipéridin-2-yl)azétidin-1-yl]-méthanone | |
| MA46342A (fr) | Dérivés de chromane, d'isochromane et de dihydroisobenzofurane en tant que modulateurs allostériques négatifs de mglur2, compositions et leur utilisation | |
| Moore et al. | Weekly intravenous bortezomib is effective and well tolerated in relapsed/refractory myeloma | |
| MA45202B1 (fr) | Composition pharmaceutique comprenant un antagoniste du récepteur minéralocorticoïde et son utilisation | |
| MA31446B1 (fr) | Inhibiteurs de raf pour le traitement du cancer de la thyroide | |
| MA49396A (fr) | Traitement de la migraine avec acétyl-leucine | |
| MA53521B1 (fr) | Nouveaux composés inhibiteurs de la protéase mpro et de la réplication du sars-cov2, leurs formulations et applications | |
| MA34327B1 (fr) | Dérivés de flufénoxine pour le traitement et la prévention des pathologies amyloïdes | |
| FR3092580B1 (fr) | Nouveaux dérivés azobenzènes, leur procédé de préparation et leur utilisation pour le traitement thérapeutique associé à des radiations ionisantes |